Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 1 2014
Print RSS Feed

Breaking News

Related Searches:
January 4, 2011
Bioniche Life Sciences, Inc. will reorganize its corporate leadership team in an effort to increase efficiency and better position the company for strategic growth.  Read More »
January 3, 2011
Akorn, Inc.’s joint venture, Akorn-Strides LLC, has entered into a purchase agreement with Pfizer to sell 16 ANDAs and six filed ANDAs.   Read More »
January 3, 2011
BASi has entered into a Preferred Provider Agreement with NJ-based Pharmasset, Inc., a clinical-stage pharmaceutical company specializing in novel drugs to treat viral infections, to provide preclinical services for pre-IND and post-IND activities.  Read More »
January 3, 2011
Dominique Baly has been appointed president of Sartorius’ group laboratory business, responsible for cross-divisional management of marketing, sales and service.  Read More »
January 3, 2011
Angie Inouye has been appointed director of business development for Consumer Product Testing Co.   Read More »
January 3, 2011
Ecron Acunova and Newcastle University have partnered to explore ways of working together in the area of clinical trials.   Read More »
December 29, 2010
Revenues down, but improving in 2H10  Read More »
December 29, 2010
FDA needs more time to review  Read More »
December 29, 2010
Lack of efficacy cited  Read More »
December 29, 2010
Rhucin application at FDA  Read More »
December 29, 2010
CEO search commences  Read More »
December 22, 2010
Merrion Pharmaceuticals and Novo Nordisk have signed a collaboration and option agreement to evaluate the ability of Merrion's GIPET technology to boost the oral bioavailability of an undisclosed compound.  Read More »
December 22, 2010
GlaxoSmithKline and Theravance have initiated a Phase IIb study to evaluate the efficacy and safety of GSK961081 (‘081), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).  Read More »
December 22, 2010
Ligand Pharmaceuticals and Pfizer have sublicensed Tanaproget, also known as NSP-989, to a multi-national pharmaceutical company.  Read More »
December 22, 2010
Corcept Therapeutics Inc. achieved positive results from its Phase III study of Corlux for the treatment of Cushing's Syndrome.  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On